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Abstract 
Two novel Lycopodium alkaloids, huperphlegmines A and B (1 and 2), were isolated from the 
aerial parts of Huperzia phlegmaria collected in Vietnam, together with the five known 
compounds lycophlegmariol A (3), phlegmariurine B (4), 5-hydroxymethyl-2-furaldehyde (5), 
rhemanone C (6), and loliolide (7). The chemical structures of the present compounds were 
elucidated by means of 1D and 2D NMR and HRESIMS spectroscopy, and by comparisons to 
the reported data in the literature. Compounds 1 and 2 showed moderate acetylcholinesterase 
inhibitory activities, with IC50 values of 25.95 ± 0.67 and 29.14 ± 0.77 µg/ml, respectively. 
 
Keywords: Huperzia phlegmaria, Lycopodium alkaloid, huperphlegmine, acetylcholinesterase 
inhibitory activity. 
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1. Introduction 
Huperzia phlegmaria (L.) Rothm. (Lycopodiaceae) [synonym: Lycopodium 
phlegmaria L.] is an epiphytic club moss found on tree trunks and rocks in forests located at 
heights of 100-2,400 m in China, Cambodia, India, Japan, Laos, Nepal, Thailand, Vietnam, 
Pacific islands, Paleotropics, and South America [1]. All parts of this plant have been used in 
traditional Chinese medicine for the treatment of rheumatic pain, arthritis, traumatic injury, 
sore throat, edema, and urticaria for many years [2]. Furthermore, this plant is also used as a 
potential medicinal herb for the treatment of several brain diseases, such as Alzheimer’s disease 
[3]. Previous phytochemical investigations of H. phlegmaria revealed that its main constituents 
are serratane-type triterpenes [4-6], Lycopodium alkaloids [7-9], and abietane diterpenes [6]. 
Huperzine A, the Lycopodium alkaloid being tested as an anti-Alzheimer’s disease drug 
candidate [10, 11], has also been isolated from H. phlegmaria, as in the case of the other 
Huperzia species. Remarkably, H. phlegmaria reportedly contains high concentrations of 
huperzine A, ranging from 44-345 µg g-1 [12], which may account for the effectiveness of this 
plant in the treatment of several brain diseases. However, the presence of other constituents 
that are also effective for brain diseases in this plant has not been excluded, since the efficacy 
of the crude drug is generally associated with multiple components.  
In our previous search for secondary metabolites with acetylcholinesterase (AChE) 
inhibitory activity in Vietnamese H. phlegmaria, we isolated several terpenoids and a known 
alkaloid with fawcettimine-related structures [13]. Furthermore, we recently identified two 
Lycopodium alkaloids, huperphlegmines A and B (1-2), with an unprecedented skeleton and 
a 2,5-substituted dihydrofuran moiety, together with five known compounds, lycophlegmariol 
A (3) [6], phlegmariurine B (4) [14], 5-hydroxymethyl-2-furaldehyde (5) [15], rhemanone C 
(6) [16], and loliolide (7) [17], from this plant (Fig. 1). Herein, we describe the isolation and 
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structural elucidation of 1 and 2, as well as the AChE inhibitory activities of the isolates, except 
for 4. Remarkably, the new compounds 1 and 2 exhibited moderate AChE inhibitory activities. 
 
2. Experimental 
2.1. General experimental procedures 
UV spectra were recorded on a Shimadzu UV-1800 spectrophotometer (Shimadzu, 
Kyoto, Japan). Infrared spectra were recorded on an IR Prestige-21 spectrometer (Shimadzu, 
Kyoto, Japan). Optical rotations were measured on a JASCO P-2100 polarimeter (Hachioji, 
Tokyo, Japan). High-resolution electron spray ionization mass spectrometry (HRESIMS) data 
were acquired, using a micrOTOF-Q 10187 mass spectrometer (Bruker, Massachusetts, USA). 
NMR spectra were recorded using a Bruker Avance 500 spectrometer (1H NMR for 500 MHz, 
13C NMR for 125 MHz) (Bruker, MA, USA), with TMS as an internal reference. Column 
chromatography was performed using silica gel (60 N, spherical, neutral, 40-50 µm, Kanto 
Chemical Co., Inc., Tokyo, Japan), Cosmosil 75C18-OPN (Nacalai Tesque Inc., Kyoto, Japan), 
YMC RP-18 (Fuji Silysia Chemical Ltd., Kasugai, Aichi, Japan), and Sephadex LH-20 
(Dowex® 50WX2-100, Sigma–Aldrich, USA). Analytical TLC was performed on pre-coated 
silica gel 60F254 and RP-18 F254 plates (0.25 or 0.50 mm thickness, Merck KGaA, Darmstadt, 
Germany). AChE, acetylthiocholine (ACTI), 5,5-dithio-bis(2-nitrobenzoic acid) (DTNB), and 
galanthamine hydrobromide were purchased from Sigma-Aldrich (USA). Dimethyl sulfoxide 
(DMSO) was purchased from Merck (Darmstadt, Germany). All chemicals used were of the 
highest grade available. 
 
2.2. Plant material 
The aerial parts of Huperzia phlegmaria (L.) Rothm. were collected from Quang Tri 
province, Vietnam, 16°55'42.5"N 106°36'30.3"E; 16°56'40.4"N 106°33'49.9"E, in June 2016, 
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and were identified by Dr. Nguyen The Cuong, Institute of Ecology and Biological Resources, 
VAST, Vietnam. A voucher specimen (No. HP01) was deposited at the Faculty of Pharmacy, 
Hue University of Medicine and Pharmacy, Vietnam. 
 
2.3. Extraction and isolation 
The dried aerial parts of H. phlegmaria (1.5 kg) were extracted with MeOH (3 times, 
5.0 L each) at room temperature to yield 75 g of a dark solid extract. This extract was then 
dissolved in 3% tartaric acid (1.0 L) and filtered to separate the solid residues (solid A). The 
remaining acidic solution was adjusted to pH 10 with saturated aqueous Na2CO3, and 
partitioned with CH2Cl2 (3 times, 2.0 L each) to obtain the total alkaloidal fraction (HC, 8 g), 
after removal of the solvent in vacuo. 
The alkaloidal fraction was chromatographed on a normal phase silica gel column, 
eluted with a stepwise gradient of CH2Cl2–MeOH (40:1 to 10:1, v/v) to obtain 6 sub-fractions, 
Fr.1–Fr.6. Fr.5 (2.87 g) was subjected to Sephadex LH-20 column chromatography, eluted with 
MeOH to obtain 5 sub-fractions, Fr.5.1-Fr.5.5. Fr.5.3 (1.6 g) was then applied to a YMC RP-
18 column, eluted with acetone–MeOH–water (1:3:1, v/v) to yield 7 fractions, Fr.5.3.1–
Fr.5.3.7. Fr.5.3.4 (789 mg) was chromatographed on a normal phase silica gel column, eluted 
with CH2Cl2–acetonitrile-ethylamine (10:1:0.1, v/v), followed by a Sephadex LH-20 column 
eluted with MeOH–water (4:1, v/v), and then subjected to preparative reversed phase HPLC 
(Zorbax SB – C18 5µm, 9.4 × 250mm) using MeOH-water (60:40, flow rate 2 mL/min) as the 
eluent, to afford 1 (38.0 mg) and 2 (21.0 mg). Fr.3 (1.32 g) was separated on a Sephadex LH-
20 column eluted with CH2Cl2-MeOH (9:1, v/v) to obtain 4 sub-fractions, Fr.3.1 – Fr.3.4, and 
further purification of HC3.3 (660 mg) yielded compound 4 (10.2 mg). 
The solid A (57 g) was washed with distilled water until neutral, and extracted with 
EtOAc to yield the EtOAc fraction (HE, 38 g). The EtOAc fraction was chromatographed on 
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a normal phase silica gel column, eluted with a gradient of CH2Cl2–MeOH (100:0, 50:50, 0:100, 
v/v), to obtain 3 fractions (HE1–HE3), according to their TLC profiles. The fraction HE2 (4.92 
g) was subjected to Sephadex LH-20 column chromatography, eluted with CH2Cl2-MeOH (9:1, 
v/v), to obtain 5 sub-fractions, HE2.1-HE2.5. The purification of HE2.2 (1.81 g) afforded 5 
(3.4 mg), 6 (4.5 mg), and 7 (5.7 mg). A portion (7.5 g) of HE3 was chromatographed on a 
normal phase silica gel column, eluted with a gradient of CH2Cl2–acetone (60:0 to 1:1, v/v), to 
obtain 12 sub-fractions, HE3.1–HE3.12, and the purification of HE3.8 (1.02 g) yielded 3 (15.0 
mg). 
Huperphlegmine A (1): Yellow oil; [a]D22 -65 (c 0.1, MeOH); IR (KBr) nmax (cm-1): 
3439, 2926, 1701, 1612, 1570, 1456, 1169, 1020, 901, 795; UV (MeOH) λmax (log e): 347 
(4.55); 1H NMR (500 MHz, CD3OD) and 13C NMR (125 MHz, CD3OD): see Table 1; 
HRESIMS m/z 397.2122 [M+H]+ (calcd. for C23H29O4N2, 397.2127). 
Huperphlegmine B (2): Yellow oil;  -162 (c 0.1, MeOH); IR (KBr) nmax (cm-1): 
3402, 2930, 1699, 1609, 1570, 1448, 1169, 1020, 901, 795; UV (MeOH) λmax (log e): 349 
(4.57); 1H NMR (500 MHz, CD3OD) and 13C NMR (125 MHz, CD3OD): see Table 1; 
HRESIMS m/z 397.2122 [M+H]+ (calcd. for C23H29O4N2, 397.2127). 
 
2.4. AChE inhibition assay 
The acetylcholinesterase inhibitory assay was performed in triplicate in 96-well microplates, 
and the absorbance was recorded using an ELISA microplate reader (EMR-500, LABOMED 
INC., CA, USA). The AChE inhibitory assay was performed by the colorimetric method 
reported by Ellman, with slight modifications [18]. ACTI was used as the substrate to examine 
the inhibitory effect of the samples on the AChE activities. The reaction mixture, containing 
140 µL Tris-HCl buffer (pH 8.0), 20 µL of the tested sample solution, and 20 µL of the AChE 
solution (0.25 units/mL), was incubated at room temperature for 15 min, and the reaction was 
22[ ]Da
 7 
then initiated by adding 10 µL of 0.24 mM ACTI, along with 10 µL of 0.24 mM Ellman’s 
reagent (DTNB), which produces a yellow 5-thio-2-nitrobenzoate anion. The mixture was 
incubated further at room temperature for 15 min, and the optical density was measured at 405 
nm to calculate the percentage inhibition. Galanthamine was used as a positive control. All 
tested samples and the positive control were dissolved in 10% DMSO (analytical grade). The 
percentage inhibition (I %) was calculated using the following equation, in which Asample is the 
absorbance of the tested compound-containing reaction and Acontrol is the absorbance of the 
control reaction. 
 I % = (1 –Asample /Acontrol) × 100 
The AChE inhibitory activity of each compound was expressed as the concentration (µg/ml) 
required to inhibit the hydrolysis of the substrate by 50% (IC50 value). A range of 
concentrations of the tested compounds was used, so the IC50 value could be calculated from 
the logarithmic dose-inhibition curve. 
 
3. Results and discussion 
The methanol extract of the aerial parts of H. phlegmaria was treated with acid and 
purified by a combination of chromatographic methods, including normal and reverse phase 
open column chromatography, Sephadex LH-20 chromatography, and reversed phase HPLC, 
to furnish two unprecedented Lycopodium alkaloids, 1 and 2, and five known compounds 
(3-7). 
 
Compound 1 was obtained as a yellow oil, with negative optical rotation ([a]D22 -65 (c 
0.1, MeOH)). The HRESIMS analysis of the molecular ion clusters [M+H]+ (m/z 397.2122) 
revealed the molecular formula to be C23H28O4N2, in conjunction with the NMR data analysis, 
suggesting that 1 has eleven degrees of unsaturation. Its IR spectrum revealed the strong 
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absorption bands at 3439 and 1701 cm-1, corresponding to hydroxyl and carbonyl groups. The 
UV spectrum indicated the presence of the aromatic ring (lmax 347 nm). The 1H NMR spectrum 
of 1 (Table 1) showed typical proton signals for an olefinic methine [δH 7.09 (d, J = 1.5 Hz, H-
1¢), two heteroaromatic methines [δH 6.88 (d, J = 3.5 Hz, H-3¢), 6.52 (d, J = 3.5 Hz, H-4¢)], an 
oxymethylene [δH 4.60 (2H, s, H2-6¢)], an N-methyl group [δH 2.51 (3H, s, H3-17)], and a 
secondary methyl group [δH 1.24 (3H, d, J = 7.0 Hz, H3-16)], along with 5 methine and 5 
methylene groups. The 13C NMR and HSQC spectra of 1 (Table 1) revealed twenty-three 
signals, including two carbonyl carbons [δC 213.8 (C-14), 210.5 (C-5)], two oxygenated sp2 
quaternary carbons [δC 160.1 (C-5¢), 152.2 (C-2¢)], an sp2 quaternary carbon [δC 138.9 (C-6)], 
an sp2 methine carbon [δC 120.9 (C-1¢)], two heteroaromatic sp2 methine carbons [δC 120.5 (C-
3¢), 111.5 (C-4¢)], two sp3 quaternary carbons [δC 81.6 (C-13), 63.6 (C-12)], five sp3 methine 
carbons [δC 66.2 (C-9), 64.7 (C-3), 61.3 (C-4), 46.9 (C-7), 43.5 (C-15)], an oxygenated 
methylene carbon [δC 57.6 (C-6¢)], an N-methyl carbon [δC 47.0 (C-17)], five methylene 
carbons [δC 46.5 (C-1), 37.1 (C-2), 36.7 (C-11), 34.7 (C-8), 20.5 (C-10)], and a methyl carbon 
(δC 18.6 (C-1), as well as the proton signals for five methylenes [δH 3.16 (dt, J = 12.5, 3.5 Hz, 
H-1a), 2.56 (overlap, H-1b), 2.27 (2H, m, H2-8), 2.19 (m, H-10a), 1.79 (m, H-10b), 2.09 (m, 
H-11a), 1.58 (dt, J = 13.0, 10.5 Hz, H-11b), 1.99 (m, H-2a), 1.70 (m, H-2b)] and five methines 
[δH 4.26 (dd, J = 9.5, 6.5 Hz, H-9), 3.67 (q-like, J = 3.0 Hz, H-3), 3.44 (dt, J = 9.0, 2.0 Hz, H-
7), 2.59 (d, J = 3.5 Hz, H-4), 2.40 (m, H-15)]. 
In the COSY spectrum (Fig. 2), the correlations of H-1a/H2-2, H-1b/H-2a, H-2b/H-3/H-
4, H-7/H2-8/H-15/H3-16, H-9/H-10a/H-11a, H-10b/H-11b, and H-3¢/H-4¢ were observed. The 
HMBC correlations of H-3¢ to C-1¢/C-2¢/C-4¢/C-5¢, H-4¢ to C-2¢/C-3¢/C-5¢, and H2-6¢ to C-4¢/C-
5¢ (Fig. 2) suggested the presence of a 2,5-disubstituted dihydrofuran moiety with olefinic and 
hydroxymethylene groups as the side chains in the structure of 1. The presence of a 16-methyl-
14-indenone ring (numbering according to 1) involving C-7-C-16 was verified by the HMBC 
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correlations from H-9 to C-13/C-14, H-11a to C-12/C-13, H-7 to C-12, and H3-16 to C-8/C-
14/C-15. Furthermore, the HMBC correlations from H-4 to C-5/C-6/C-12, H-7 to C-5/C-6, H2-
8 to C-6, and H-1¢ to C-5/C-6/C-7/C-2¢/C-3¢ led not only to the construction of a 
cyclopentanone ring involving C-4, C-5, C-6, C-7, and C-12, but also to the connection of this 
ring to the 5-hydroxymethylenedihydrofuran moiety via a D6 double bond at C-2. In addition, 
the COSY correlations of H-1a/H2-2/H-3/H-4 and H-1b/H-2a, and the HMBC correlations 
from H-17 to C-1/C-9 and from H-4 to C-3, indicated that the methylated nitrogen atom and 
C-3 were connected to C-9 on the cyclopentane ring of the indenone ring and C-4 on the 
cyclopentanone ring, respectively, suggesting the presence of an N-methylazonane ring formed 
by the linkage of the nitrogen atom, C-1-C-4, and C-9-C-12. On the basis of the molecular 
formula and the observed NMR data mentioned above, the remaining nitrogen atom should be 
a secondary amine and one more ring was needed to fulfill the degree of saturation. Thus, the 
amine moiety was attached to C-3 and C-13, which is also supported by the observation of the 
HMBC correlation from H-3 to C-13, and a pyrrolidine ring involving the secondary amine, 
C-3, C-4, C-12, and C-13 was constructed in the structure of 1. Based on these data, the planar 
structure of 1 was determined, as shown in Fig. 2. 
The relative configuration of 1 was elucidated on the basis of the NOESY experiment 
(Fig. 3). The NOESY correlations from H-7/H2-8 to H-3¢ indicated the E configuration of the 
D6 double bond. The cross peaks from H-4/H-10b, H-4/H-11a, and H-7/H-11b in the NOESY 
spectrum suggested the a-orientations of H-4 and H-7, and the C-10 and C-11 dimethylene 
moieties. In contrast, the NOESY correlations of H-3/H-8 and the lack of correlations of H-
3/H2-10 and H-3/H2-11 indicated that H-3 and the C-8 methylene group are b-oriented. 
Furthermore, the NOESY spectra indicated that the C-16 methyl moiety is located on the 
opposite side of H-7, as verified by observations of the NOESY correlation of H-7/H-15, as 
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well as the lack of that of H-7/H3-16. Consequently, the structure of 1 was elucidated as 
depicted in Fig. 1, and named huperphlegmine A. 
Compound 2 was isolated as a yellow oil, with negative optical rotation ([a]D22 -162 (c 
0.1, MeOH). The HRESIMS analysis indicated the same molecular formula of C23H28O4N2 as 
that of 1. IR spectrum of 2 showed the strong absorption bands at 3402 and 1699 cm-1, 
corresponding to hydroxyl and carbonyl groups and the UV spectrum indicated the presence 
of the aromatic ring (lmax 349 nm), as in the case of 1. The 1H and 13C NMR spectroscopic data 
of 2 (Table 1) were quite similar to those of 1, except for those of the C-7 methine (δH 3.51, δC 
43.5), C-14 carbonyl (δC 215.4), C-15 methine (δH 2.77, δC 40.0), and C-16 methyl (δH 16.5, 
δC 16.5) groups. However, the 2D-NMR analysis indicated that 2 possesses the same planar 
structure as that of 1, suggesting that 2 is a stereoisomer of 1. In order to clarify this hypothesis, 
the relative configuration of 2 was determined by a NOESY experiment (Fig. 3). Remarkably, 
in contrast to the NOESY data of 1, H-7 (δH 3.51) correlated with H3-16 (δH 1.32), but not with 
H-15 (δH 2.77). Compound 2 was thus suggested to be the 15-epimer of 1. This proposal may 
also be supported by the significant difference of the chemical shift values of C-7 between 1 
and 2, due to the shielding effect of the C-13 methyl group on the C-7 position. In addition, the 
H2-8/H-3¢ cross peak observed in the NOESY spectrum of 1 was not present, and instead, a 
correlation of H-1¢ (δH 7.06)/H-3¢ (δH 6.85) appeared in the NOESY spectrum of 2. 
Furthermore, the NOESY spectrum showed a correlation between H3-16 and H-6¢ (δH 4.60), 
which was not observed in that of 1. This evidence suggested that the oxygen atom in the furan 
ring of 2 is oriented toward C-8. The differences in the orientations of the furan ring between 
1 and 2 might be explained by the rotation around the C-1¢/C-2¢ bond of these moieties. Thus, 
the structure of 2 was elucidated as shown in Fig. 1, and was named huperphlegmine B. 
The structures of the isolated known compounds 3-7 were identified by comparisons 
of their spectroscopic data with those reported in the literature. The Lycoposium alkaloids, 
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slycopalhine A [19] and obscurumine H [20], with the C-9-N-2¢ linkage-containing six ring 
C16N2 skeleton similar to those of 1 and 2, were isolated from Palhinhaea cernua (syn.: 
Lycopodium cernua) and L. obscurum, respectively. However, to the best of our knowledge, 
this is the first demonstration of the isolation of Lycoposium alkaloids with the novel C16N2-
type skeleton consisting of five rings, including the new C-9-C-13 linkage. Presumably, 1 and 
2 are generated from obscurinine via (1) its oxidation at C-14 to form the 15-epimer 
intermediates A, (2) the hydrogenation and oxidation of A for conversion to the intermediates 
B, (3) the Polonovski-type reaction of B followed by a sequential cyclization of their 
intermediates C for the formation of the intermediates D, (4) the aldol condensation of D with 
rhemanone C (6), which was also isolated from this plant in the present study, and the 
dihydroxylation to connect the 2,5-disubstituted dihydrofuran side chain (Fig. 4). 
The AChE inhibitory activities of the isolates, except for the previously reported 
compound 4 [21], were assessed at various concentrations. Galanthamine was used as a 
positive control. The results are summarized in Table 2. Among the tested compounds, only 
the novel compounds 1 and 2 showed moderate inhibitory activities against AChE, with IC50 
values of 25.95 ± 0.67 and 29.14 ± 0.77 µg/ml, respectively. These observations suggest that 
1 and 2 contribute to the previously reported efficacy of this plant for the treatment of several 
brain diseases. 
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Figure legends. 
Fig. 1. Structures of compounds 1-7 isolated from the aerial parts of H. phlegmaria. 
Fig. 2. Key HMBC (1H→13C, arrows) and COSY (bold lines) correlations of 1. 
Fig. 3. Key NOESY correlations (dashed arrows) of compounds 1 and 2. 
Fig. 4. Plausible biogenetic pathway of 1 and 2. 
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Table 1. 1H (500 MHz) and 13C (125 MHz) NMR spectroscopic data for 1 and 2 in CD3OD 
Position 1
 2 
δC δH (mult., J in Hz) δC δH (mult., J in Hz) 
1a 46.5 3.16 (dt, 12.5, 3.5) 46.6 3.18 (dt, 12.5, 3.0) 
1b  2.56a   2.60* 
2a 37.1 1.99 (m) 37.0 2.00 (m) 
2b  1.70 (m)  1.71 (m) 
3 64.7 3.67 (q-like, 3.0) 64.8 3.76 (q-like, 3.0) 
4 61.3 2.59 (d, 3.5) 61.1 2.57 (d, 3.0) 
5 210.5 – 210.3 – 
6 138.9 – 139.3 – 
7 46.9 3.44 (dt, 9.0, 2.0) 43.5 3.51 (ddd, 12.0, 5.5, 1.5) 
8 34.7 2.27 (m) 34.6 2.80 (m) 
8b    2.00* 
9 66.2 4.26 (dd, 9.5, 6.5) 65.8 4.35 (dd, 9.5, 6.0) 
10a 20.5 2.19 (m) 20.7 2.20 (m) 
10b  1.79 (m)  1.79 (m) 
11a 36.7 2.09 (m) 36.4 2.07 (m) 
11b  1.58 (td, 13.0, 
10.5) 
 1.49 (td, 13.5, 10.5) 
12 63.6 – 65.7 – 
13 81.6 – 81.8 – 
14 213.8 – 215.4 – 
15 43.5 2.40 (m) 40.0 2.77 (m) 
16 18.6 1.24 (d, 7.0) 16.5 1.32 (d, 7.5) 
17 47.0 2.51 (s) 47.1 2.52 (s) 
1¢ 120.9 7.09 (d, 1.5) 120.4 7.06 (d, 1.5) 
2¢ 152.2 – 152.3 – 
3¢ 120.5 6.88 (d, 3.5) 120.6 6.85 (d, 3.5) 
4¢ 111.5 6.52 (d, 3.5) 111.5 6.52 (d, 3.5) 
5¢ 160.1 – 160.1 – 
6¢ 57.6 4.60 (s) 57.7 4.60 (s) 
aOverlapping resonances within the same column. 
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Table 2. In vitro AChE inhibitory activities of compounds 1-3 and 5-7 from H. phlegmaria 
Compounds IC50 ± SD (µg/ml) 
1 25.95 ± 0.67 
2 29.14 ± 0.77 
3 >1,000 
5 >1,000 
6 >1,000 
7 >1,000 
Galanthamine* 0.33 ± 0.01 
*Positive control. 
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Figure 1 
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